206 related articles for article (PubMed ID: 29185480)
1. Initial Cross-Over Test of A Positive Allosteric Modulator of Alpha-7 Nicotinic Receptors to Aid Cessation in Smokers With Or Without Schizophrenia.
Perkins KA; Roy Chengappa KN; Karelitz JL; Boldry MC; Michael V; Herb T; Gannon J; Brar J; Ford L; Rassnick S; Brunzell DH
Neuropsychopharmacology; 2018 May; 43(6):1334-1342. PubMed ID: 29185480
[TBL] [Abstract][Full Text] [Related]
2. Diverse strategies targeting α7 homomeric and α6β2* heteromeric nicotinic acetylcholine receptors for smoking cessation.
Brunzell DH; McIntosh JM; Papke RL
Ann N Y Acad Sci; 2014 Oct; 1327(1):27-45. PubMed ID: 24730978
[TBL] [Abstract][Full Text] [Related]
3. Effects of the nicotinic receptor antagonist mecamylamine on ad-lib smoking behavior, topography, and nicotine levels in smokers with and without schizophrenia: a preliminary study.
McKee SA; Weinberger AH; Harrison EL; Coppola S; George TP
Schizophr Res; 2009 Dec; 115(2-3):317-24. PubMed ID: 19700263
[TBL] [Abstract][Full Text] [Related]
4. Effect of nicotine lozenges on affective smoking withdrawal symptoms: secondary analysis of a randomized, double-blind, placebo-controlled clinical trial.
Shiffman S
Clin Ther; 2008 Aug; 30(8):1461-75. PubMed ID: 18803988
[TBL] [Abstract][Full Text] [Related]
5. Phase IIb Trial of an α7 Nicotinic Receptor Partial Agonist With and Without Nicotine Patch for Withdrawal-Associated Cognitive Deficits and Tobacco Abstinence.
Schuster RM; Pachas GN; Stoeckel L; Cather C; Nadal M; Mischoulon D; Schoenfeld DA; Zhang H; Ulysse C; Dodds EB; Sobolewski S; Hudziak V; Hanly A; Fava M; Evins AE
J Clin Psychopharmacol; 2018 Aug; 38(4):307-316. PubMed ID: 29912798
[TBL] [Abstract][Full Text] [Related]
6. 3-Furan-2-yl-N-p-tolyl-acrylamide, a positive allosteric modulator of the α7 nicotinic receptor, reverses schizophrenia-like cognitive and social deficits in rats.
Potasiewicz A; Hołuj M; Kos T; Popik P; Arias HR; Nikiforuk A
Neuropharmacology; 2017 Feb; 113(Pt A):188-197. PubMed ID: 27717880
[TBL] [Abstract][Full Text] [Related]
7. Combining CDP-choline and galantamine: Effects of a selective α7 nicotinic acetylcholine receptor agonist strategy on P50 sensory gating of speech sounds in healthy volunteers.
Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Illivitsky V; Knott V
J Psychopharmacol; 2019 Jun; 33(6):688-699. PubMed ID: 30920339
[TBL] [Abstract][Full Text] [Related]
8. First in human trial of a type I positive allosteric modulator of alpha7-nicotinic acetylcholine receptors: Pharmacokinetics, safety, and evidence for neurocognitive effect of AVL-3288.
Gee KW; Olincy A; Kanner R; Johnson L; Hogenkamp D; Harris J; Tran M; Edmonds SA; Sauer W; Yoshimura R; Johnstone T; Freedman R
J Psychopharmacol; 2017 Apr; 31(4):434-441. PubMed ID: 28196430
[TBL] [Abstract][Full Text] [Related]
9. Prediction of abstinence at 10 weeks based on smoking status at 2 weeks during a quit attempt: secondary analysis of two parallel, 10-week, randomized, double-blind, placebo-controlled clinical trials of 21-mg nicotine patch in adult smokers.
Ferguson SG; Gitchell JG; Shiffman S; Sembower MA
Clin Ther; 2009 Sep; 31(9):1957-65. PubMed ID: 19843485
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled study of the kappa opioid receptor antagonist, CERC-501, in a human laboratory model of smoking behavior.
Jones JD; Babalonis S; Marcus R; Vince B; Kelsh D; Lofwall MR; Fraser H; Paterson B; Martinez S; Martinez DM; Nunes EV; Walsh SL; Comer SD
Addict Biol; 2020 Jul; 25(4):e12799. PubMed ID: 31240842
[TBL] [Abstract][Full Text] [Related]
11. Quitting by gradual smoking reduction using nicotine gum: a randomized controlled trial.
Shiffman S; Ferguson SG; Strahs KR
Am J Prev Med; 2009 Feb; 36(2):96-104.e1. PubMed ID: 19135903
[TBL] [Abstract][Full Text] [Related]
12. Novel Mineral-Vitamin Treatment for Reduction in Cigarette Smoking: A Fully Blinded Randomized Placebo-Controlled Trial.
Reihana PK; Blampied NM; Rucklidge JJ
Nicotine Tob Res; 2019 Oct; 21(11):1496-1505. PubMed ID: 31665746
[TBL] [Abstract][Full Text] [Related]
13. Impact of an electronic cigarette on smoking reduction and cessation in schizophrenic smokers: a prospective 12-month pilot study.
Caponnetto P; Auditore R; Russo C; Cappello GC; Polosa R
Int J Environ Res Public Health; 2013 Jan; 10(2):446-61. PubMed ID: 23358230
[TBL] [Abstract][Full Text] [Related]
14. A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia.
Evins AE; Cather C; Culhane MA; Birnbaum A; Horowitz J; Hsieh E; Freudenreich O; Henderson DC; Schoenfeld DA; Rigotti NA; Goff DC
J Clin Psychopharmacol; 2007 Aug; 27(4):380-6. PubMed ID: 17632223
[TBL] [Abstract][Full Text] [Related]
15. Nicotine withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia.
Dalack GW; Becks L; Hill E; Pomerleau OF; Meador-Woodruff JH
Neuropsychopharmacology; 1999 Aug; 21(2):195-202. PubMed ID: 10432467
[TBL] [Abstract][Full Text] [Related]
16. Dianicline, a novel α4β2 nicotinic acetylcholine receptor partial agonist, for smoking cessation: a randomized placebo-controlled clinical trial.
Tonstad S; Holme I; Tønnesen P
Nicotine Tob Res; 2011 Jan; 13(1):1-6. PubMed ID: 21041839
[TBL] [Abstract][Full Text] [Related]
17. Brain nicotinic acetylcholine receptor availability and response to smoking cessation treatment: a randomized trial.
Brody AL; Mukhin AG; Mamoun MS; Luu T; Neary M; Liang L; Shieh J; Sugar CA; Rose JE; Mandelkern MA
JAMA Psychiatry; 2014 Jul; 71(7):797-805. PubMed ID: 24850280
[TBL] [Abstract][Full Text] [Related]
18. Dose-dependent effects of Varenicline on tobacco craving and withdrawal in tobacco smokers with and without schizophrenia.
Johnstone S; Sorkhou M; Rabin RA; George TP
Drug Alcohol Depend; 2022 May; 234():109412. PubMed ID: 35395548
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of the nicotine patch and gum for the treatment of adolescent tobacco addiction.
Moolchan ET; Robinson ML; Ernst M; Cadet JL; Pickworth WB; Heishman SJ; Schroeder JR
Pediatrics; 2005 Apr; 115(4):e407-14. PubMed ID: 15805342
[TBL] [Abstract][Full Text] [Related]
20. Positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors reverse ketamine-induced schizophrenia-like deficits in rats.
Nikiforuk A; Kos T; Hołuj M; Potasiewicz A; Popik P
Neuropharmacology; 2016 Feb; 101():389-400. PubMed ID: 26232639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
